医学事务评论（美国） - 重症气喘的标靶治疗（生物製剂）

根据这项对100名治疗气喘的美国过敏症专科医生和肺病专家的最新调查，几大品牌的气喘医疗事务团队的表现在几个关键领域仍有待提高。

本报告研究了美国医疗事务的现状以及它如何满足治疗气喘的医生的高期望。它也比较了各公司医疗事务团队对每种主要气喘药物的当前表现。

领导品牌

According to this latest survey of 100 US allergists and pulmonologists treating asthma, the performance of asthma medical affairs teams for some high-profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating asthma. It compares the current performance of medical affairs teams for several leading treatments for asthma from various companies.

Key Questions Answered:

• 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
• 2. In what ways do physicians currently use the services provided by Medical Affairs teams?
• 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
• 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
• 5. How successful are Medical Affairs teams at meeting physician needs?
• 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
• 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
• 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.